High risk and rapid appearance of multidrug resistance during tuberculosis treatment in Moldova
Închide
Conţinutul numărului revistei
Articolul precedent
Articolul urmator
165 0
SM ISO690:2012
JENKINS, Helen Elizabeth, KRUDU, V., SOLTAN, Viorel, CIOBANU, Ana, DOMENTE, Liliana, COHEN, Ted. High risk and rapid appearance of multidrug resistance during tuberculosis treatment in Moldova. In: European Respiratory Journal, 2014, vol. 43, pp. 1132-1141. ISSN 0903-1936. DOI: https://doi.org/10.1183/09031936.00203613
EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core
European Respiratory Journal
Volumul 43 / 2014 / ISSN 0903-1936 /ISSNe 1399-3003

High risk and rapid appearance of multidrug resistance during tuberculosis treatment in Moldova

DOI:https://doi.org/10.1183/09031936.00203613

Pag. 1132-1141

Jenkins Helen Elizabeth12, Krudu V.3, Soltan Viorel3, Ciobanu Ana4, Domente Liliana4, Cohen Ted52
 
1 Harvard Medical School, Boston,
2 Brigham and Women's Hospital, Boston,
3 Harvard T H Chan School of Public Health, Boston,
4 Center for Health Policies and Studies,
5 Institute of Phtysiopneumology „Chiril Draganiuc”
 
 
Disponibil în IBN: 20 iulie 2023


Rezumat

Multidrug-resistant tuberculosis (MDR-TB) is a serious problem in the former Soviet Union and may appear during TB treatment. We aimed to estimate the prevalence of, timing of and factors associated with MDR-TB diagnosis during TB treatment in Moldova, which was part of the former Soviet Union. We analysed data on 3 754 confirmed non-MDR-TB cases (between January 1, 2007 and December 31, 2010) in the Moldovan TB surveillance database, where patients provided sputum specimens for drug-susceptibility testing, multiple times, during treatment. We estimated the percentage of individuals with confirmed baseline non-MDR-TB that were diagnosed with MDR-TB during treatment, documented the time at which MDR-TB was diagnosed, and used a failure-time model to identify factors associated with MDR-TB diagnosis. Between 7.2% and 9.2% of initially non-MDR-TB cases were diagnosed with MDR-TB during treatment. Half of these MDR-TB diagnoses occurred with 3 months of the initial diagnosis. An increased MDR-TB risk during treatment was associated with baseline resistance to first-line TB drugs (linear increase in risk per additional drug), previous incarceration and HIV co-infection. MDR can appear rapidly during TB treatment. Policy considerations should emphasise management during early treatment by increasing ambulatory TB treatment to prevent nosocomial transmission, and ensuring universal rapid diagnostics access to prevent acquisition and transmission of drug resistance.

Cuvinte-cheie
MeSH Adult, Coinfection, drug resistance, multiple, Bacterial, female, HIV infections, Humans, Male, middle aged, Moldova, prevalence, risk factors, time factors, treatment outcome, tuberculosis, tuberculosis, Multidrug-Resistant EMTREE drug terms ethambutol, isoniazid, rifampicin, streptomycin EMTREE medical terms adult, Age Distribution, conference paper, controlled study, drug sensitivity, female, follow up, human, Human immunodeficiency virus infection, infection risk, major clinical study, Male, medical documentation, mixed infection, Moldova, monotherapy, multidrug resistance, Multidrug Resistant Tuberculosis, prevalence, priority journal, risk assessment, risk factor, sputum examination, tuberculosis, complication, middle aged, multidrug resistance, time, treatment outcome, tuberculosis, Multidrug-Resistant